ACEA Biosciences
Hong Hanh Nguyen has a diverse work experience in the field of biosciences and research. Hong Hanh started their career as a Teaching Assistant at International University - Vietnam National University in 2012. Hong Hanh then worked as a Graduate Researcher at Chonnam National University Hospital from 2013 to 2015, focusing on CD8+T cell research and various techniques related to Cancer Immunology.
From 2015 to 2018, Hong Hanh Nguyen joined ITS Vietnam as a Product Manager, where they supervised and updated customers with the latest research trends in immunotherapy, cancer screening/diagnostics, molecular biology, and animal facility. Hong Hanh also enjoyed assisting customers with full solutions and developing new product markets.
Since 2018, Hong Hanh Nguyen has been working at ACEA Biosciences as an Associate Country Manager - Vietnam. Further details about their role and responsibilities are not provided.
Hong Hanh Nguyen earned a Bachelor of Engineering (B.Eng.) degree in Biotechnology from HCMC University of Technology, where they studied from 2007 to 2012. Hong Hanh later pursued a Master of Science (M.Sc.) degree in Immunology and Bio-medical Science at Chonnam National University, South Korea, from 2013 to 2015. Hong Hanh successfully obtained their Master of Science degree from Chonnam National University in February 2015.
This person is not in any teams
This person is not in any offices
ACEA Biosciences
ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China.The Life TechnologyBusiness Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology.The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005.ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.